These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 11218298)
1. [Thalidomide: the revival]. Grosbois B; Duguet C Rev Med Interne; 2001 Jan; 22(1):5-7. PubMed ID: 11218298 [No Abstract] [Full Text] [Related]
2. [Thalidomide in treatment of connective diseases and vasculities]. Maruotti N; Cantatore FP; Ribatti D Reumatismo; 2006; 58(3):187-90. PubMed ID: 17013434 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide. A new beginning. Valorie AM Cancer Pract; 2000; 8(2):101-3. PubMed ID: 11898173 [No Abstract] [Full Text] [Related]
4. Thalidomide--a revival story. Raje N; Anderson K N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693 [No Abstract] [Full Text] [Related]
5. Thalidomide: focus on its employment in rheumatologic diseases. Ossandon A; Cassarà EA; Priori R; Valesini G Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207 [TBL] [Abstract][Full Text] [Related]
6. [Thalidomide--a new prospective therapy in rheumatology and transplantation]. Pałgan K; Pałgan I; Dziedziczko A Wiad Lek; 2003; 56(11-12):574-6. PubMed ID: 15058168 [TBL] [Abstract][Full Text] [Related]
7. Thalidomide: current and potential clinical applications. Calabrese L; Fleischer AB Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782 [TBL] [Abstract][Full Text] [Related]
8. Thalidomide as a targeted therapy for multiple myeloma. Dan K Intern Med; 2003 Jul; 42(7):550-1. PubMed ID: 12879943 [No Abstract] [Full Text] [Related]
11. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Breitkreutz I; Anderson KC Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684 [TBL] [Abstract][Full Text] [Related]
14. The revitalization of thalidomide. Thomas DA; Kantarjian HM Ann Oncol; 2001 Jul; 12(7):885-6. PubMed ID: 11521791 [No Abstract] [Full Text] [Related]
15. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Rajkumar SV; Fonseca R; Witzig TE Arch Intern Med; 2001 Nov; 161(20):2502-3. PubMed ID: 11700165 [No Abstract] [Full Text] [Related]
16. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug]. Borges Lde G; Frõehlich PE Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820 [TBL] [Abstract][Full Text] [Related]
17. Recent studies on the thalidomide and its derivatives. Łączkowski KZ; Baranowska-Łączkowska A Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422 [No Abstract] [Full Text] [Related]
18. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Semin Oncol; 2001 Dec; 28(6):597-601. PubMed ID: 11740816 [TBL] [Abstract][Full Text] [Related]
19. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Rajkumar SV; Witzig TE Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136 [TBL] [Abstract][Full Text] [Related]
20. Is thalidomide a true anti-angiogenic molecule in multiple myeloma? Ribatti D; Vacca A Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476 [No Abstract] [Full Text] [Related] [Next] [New Search]